Overview:Aeterna Zentaris, a specialty biopharmaceutical company, is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin), an oral ghrelin receptor agonist to be administered in the diagnosis of patients with adult growth hormone deficiency, in the United States and Canada.
For partnership opportunities outside of the United States and Canada, please contact our Business Development Department at BD@aezsinc.com.
Aeterna Zentaris has a set of core values that guides all of our activities. We pledge to act with Integrity — comprising Fairness, Honesty and Perseverance especially when facing difficulties or challenges. In our everyday work, we focus on the following values while upholding the highest ethical standards: Teamwork, Transparency, Innovation, Integrity.
Recent Company/Product History:
Aeterna Zentaris announced that the U.S. Food and Drug Administration (FDA) had granted marketing approval for Macrilen™ (macimorelin) on December 20, 2017. Following this announcement on January 17, 2018, Aeterna Zentaris announced that it had entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Ireland Ltd. to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. This license and assignment agreement was acquired by Novo Nordisk on October 31st, 2018 for $145 billion plus royalties. For more information about Macrilen™ (macimorelin) visit: https://www.macrilen.com.
On January 16, 2019, Aeterna Zentaris announced that the European Medicines Agency (EMA) has granted marketing authorization for macimorelin for diagnosis of adult growth hormone deficiency (AGHD). The approval came following the Committee for Medicinal Products for Human Use (CHMP) positive opinion of macimorelin on November 19, 2018.